Sugi Predict

Sugi Predict / Targets / PARP6

PARP6

Protein mono-ADP-ribosyltransferase PARP6 · Q2NL67 · PARP6 on Sugi Atlas →

11,097 patent compounds predicted against PARP6, 8,441 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL12311751 SCHEMBL12311751 0.46 7/20
SCHEMBL1160554 SCHEMBL1160554 0.52 6/20
SCHEMBL1160972 SCHEMBL1160972 0.51 6/20
SCHEMBL1160731 SCHEMBL1160731 0.50 6/20
SCHEMBL8078589 SCHEMBL8078589 0.50 6/20
SCHEMBL13166997 SCHEMBL13166997 0.49 6/20
SCHEMBL10102431 SCHEMBL10102431 0.47 6/20
SCHEMBL1160802 SCHEMBL1160802 0.48 5/20
SCHEMBL4092851 SCHEMBL4092851 0.48 5/20
SCHEMBL1160703 SCHEMBL1160703 0.48 5/20
SCHEMBL1160966 SCHEMBL1160966 0.48 5/20
SCHEMBL1160656 SCHEMBL1160656 0.46 5/20
SCHEMBL6114174 SCHEMBL6114174 0.46 5/20
SCHEMBL1160599 SCHEMBL1160599 0.45 5/20
SCHEMBL1160650 SCHEMBL1160650 0.45 5/20
SCHEMBL1160776 SCHEMBL1160776 0.45 5/20
SCHEMBL1160578 SCHEMBL1160578 0.45 5/20
SCHEMBL1160788 SCHEMBL1160788 0.45 5/20
SCHEMBL1160701 SCHEMBL1160701 0.44 5/20
SCHEMBL1160938 SCHEMBL1160938 0.44 5/20

Clinical trials — most relevant to PARP6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer PHASE2ACTIVE_NOT_RECRUITING
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Sirtuin1 in COVID19 Patients nanUNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
Project SIRT6 Activator nanRECRUITING
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PARP6 binder may also engage these)

ProteinNameSimilarity
Q6P6P7 — 1.000 Q6P6P7 →
Q5RDU4 — 1.000 Q5RDU4 →
Q96JG6 — 0.957 Q96JG6 →
F1LSG8 — 0.957 F1LSG8 →
Q96DM3 — 0.957 Q96DM3 →
Q8CI71 — 0.956 Q8CI71 →
O14639 — 0.950 O14639 →
Q5F450 — 0.950 Q5F450 →
Q9TUZ0 — 0.947 Q9TUZ0 →
Q3MHJ2 — 0.946 Q3MHJ2 →
EXOC1 Exocyst complex component 1 0.945 landscape →
Q8R3S6 — 0.944 Q8R3S6 →
Q12800 — 0.944 Q12800 →
Q8VC42 — 0.943 Q8VC42 →
B4ZIX8 — 0.943 B4ZIX8 →
STAT5B Signal transducer and activator of transcription 5B 0.943 landscape →
Q2PG42 — 0.942 Q2PG42 →
Q9TUM3 — 0.942 Q9TUM3 →
Q5ZKV9 — 0.942 Q5ZKV9 →
Q1RLU8 — 0.941 Q1RLU8 →
Q9Y6X3 — 0.941 Q9Y6X3 →
Q5F415 — 0.940 Q5F415 →
Q32NS4 — 0.940 Q32NS4 →
A0M8U1 — 0.939 A0M8U1 →
Q9D2X5 — 0.939 Q9D2X5 →
CDC16 Cell division cycle protein 16 homolog 0.939 landscape →
Q5RBN9 — 0.939 Q5RBN9 →
Q9H1A3 — 0.939 Q9H1A3 →
P42232 — 0.939 P42232 →
Q5RF08 — 0.939 Q5RF08 →